Long standing heart disease should be better screened [7]

British Medical Journal

Volumn 321, Issue 7268, 2000, Pages 1083-1084

  Strandberg, T E ^a   Vanhanen, H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; MEVINOLIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCREENING TEST; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FINLAND; HUMANS; MASS SCREENING;

EID: 0034727346     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Ten year audit of secondary prevention in coronary bypass patients
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian simvastatin survival study (4S)
3. Frequency of lipid-lowering therapy after a coronary event in Helsinki, Finland
4. Goals and reality in lipid lowering therapy
5. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention